

KENTURN NANO. TEC. CO., LTD.**Financial Statements****With Independent Auditors' Review Report
For the Three Months Ended March 31, 2025 and 2024**

Address: No.16, East 7 Rd. Chang-Bin Industrial Park, Changhua, Taiwan (R.O.C.)
Telephone: 886-4-791-0271

The independent auditors' review report and the accompanying financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and financial statements, the Chinese version shall prevail.

Table of contents

Contents	Page
1. Cover Page	1
2. Table of Contents	2
3. Independent Auditors' Review Report	3
4. Balance Sheets	4
5. Statements of Comprehensive Income	5
6. Statements of Changes in Equity	6
7. Statements of Cash Flows	7
8. Notes to the Financial Statements	
(1) Company history	8
(2) Approval date and procedures of the financial statements	8
(3) New standards, amendments and interpretations adopted	8~10
(4) Summary of material accounting policies	10~11
(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty	11
(6) Explanation of significant accounts	11~29
(7) Related-party transactions	29
(8) Pledged assets	29
(9) Commitments and contingencies	30
(10) Losses due to major disasters	30
(11) Subsequent Events	30
(12) Other	30
(13) Other disclosures	
(a) Information on significant transactions	31
(b) Information on investees	31
(c) Information on investment in Mainland China	31
(14) Segment information	31



安侯建業聯合會計師事務所
KPMG

台中市407544西屯區文心路二段201號7樓
7F, No.201, Sec.2, Wenxin Road,
Taichung City 407059, Taiwan (R.O.C.)

電話 Tel +886 4 2415 9168
傳真 Fax +886 4 2259 0196
網址 Web kpmg.com/tw

Independent Auditors' Review Report

To the Board of Directors of Kenturn Nano. Tec. Co., Ltd.:

Introduction

We have reviewed the accompanying balance sheets of Kenturn Nano. Tec. Co., Ltd. as of March 31, 2025 and 2024, and the related statements of comprehensive income, changes in equity and cash flows for the three months ended March 31, 2025 and 2024, and notes to the financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of the financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying financial statements do not present fairly, in all material respects, the financial position of Kenturn Nano. Tec. Co., Ltd. as of March 31, 2025 and 2024, and of its financial performance and its cash flows for the three months ended March 31, 2025 and 2024 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

The engagement partners on the reviews resulting in this independent auditors' review report are Chen, Cheng-Hsueh and Chen, Yen-Hui.

KPMG

Taipei, Taiwan (Republic of China)
May 6, 2025

Notes to Readers

The accompanying financial statements are intended only to present the statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' review report and the accompanying financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and financial statements, the Chinese version shall prevail.

(English Translation of Financial Statements Originally Issued in Chinese)

KENTURN NANO. TEC. CO., LTD.**Statements of Comprehensive Income****For the three months ended March 31, 2025 and 2024****(Expressed in Thousands of New Taiwan Dollars , Except for Earnings Per Common Share)**

		For the three months ended March 31			
		2025		2024	
		Amount	%	Amount	%
4000	Operating revenue(note 6(r))	\$ 214,791	100	276,600	100
5000	Operating costs(notes 6(d), (n) and (s))	<u>159,316</u>	<u>74</u>	<u>184,954</u>	<u>67</u>
	Gross profit from operations	<u>55,475</u>	<u>26</u>	<u>91,646</u>	<u>33</u>
	Operating expenses(note 6(m), (n) and (s))				
6100	Selling expenses	8,332	4	7,327	2
6200	Administrative expenses	27,704	13	22,565	8
6300	Research and development expenses	7,679	3	4,884	2
6450	Expected credit gains(note 6(c))	<u>(596)</u>	<u>-</u>	<u>(1,131)</u>	<u>-</u>
		<u>43,119</u>	<u>20</u>	<u>33,645</u>	<u>12</u>
	Net operating income	<u>12,356</u>	<u>6</u>	<u>58,001</u>	<u>21</u>
	Non-operating income and expenses(note 6(t))				
7100	Interest income	237	-	899	-
7010	Other income	54	-	137	-
7020	Other gains and losses	9,798	4	12,958	5
7050	Finance costs(note 6(m))	<u>(2,881)</u>	<u>(1)</u>	<u>(3,004)</u>	<u>(1)</u>
		<u>7,208</u>	<u>3</u>	<u>10,990</u>	<u>4</u>
7900	Profit before income tax	19,564	9	68,991	25
7950	Less: Income tax expenses(note 6(o))	<u>3,913</u>	<u>2</u>	<u>13,798</u>	<u>5</u>
8200	Profit	<u>15,651</u>	<u>7</u>	<u>55,193</u>	<u>20</u>
8300	Other comprehensive income	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
8500	Total comprehensive income	<u>\$ 15,651</u>	<u>7</u>	<u>55,193</u>	<u>20</u>
	Earnings per share (NT dollars) (note 6(q))				
9750	Basic earnings per share	<u>\$ 0.27</u>		<u>0.94</u>	
9850	Diluted earnings per share	<u>\$ 0.27</u>		<u>0.94</u>	

See accompanying notes to financial statements.

(English Translation of Financial Statements Originally Issued in Chinese)
KENTURN NANO. TEC. CO., LTD.

Statements of Changes in Equity
For the three months ended March 31, 2025 and 2024
(Expressed in Thousands of New Taiwan Dollars)

	Ordinary shares		Retained earnings			
			Capital surplus	Legal reserve	Unappropriated retained earnings	Total
Balance at January 1, 2024	\$	585,216	210,536	91,595	373,264	464,859
Profit for the period		-	-	-	55,193	55,193
Other comprehensive income for the period		-	-	-	-	-
Total comprehensive income for the period		-	-	-	55,193	55,193
Balance at March 31, 2024	\$	<u>585,216</u>	<u>210,536</u>	<u>91,595</u>	<u>428,457</u>	<u>1,315,804</u>
Balance at January 1, 2025	\$	585,216	210,536	107,534	491,993	599,527
Profit for the period		-	-	-	15,651	15,651
Other comprehensive income for the period		-	-	-	-	-
Total comprehensive income for the period		-	-	-	15,651	15,651
Balance at March 31, 2025	\$	<u>585,216</u>	<u>210,536</u>	<u>107,534</u>	<u>507,644</u>	<u>1,410,930</u>

See accompanying notes to financial statements.

(English Translation of Financial Statements Originally Issued in Chinese)
KENTURN NANO. TEC. CO., LTD.

Statements of Cash Flows

For the three months ended March 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollars)

	For the three months ended March 31	
	2025	2024
Cash flows from (used in) operating activities:		
Profit before tax	\$ 19,564	68,991
Adjustments:		
Adjustments to reconcile profit (loss):		
Depreciation expense	18,835	17,740
Amortization expense	1,007	564
Expected credit gains	(596)	(1,131)
Interest expense	2,881	3,004
Interest income	(237)	(899)
(Gains) losses on valuation of inventories	(1,397)	723
Total adjustments to reconcile profit	20,493	20,001
Changes in operating assets and liabilities:		
Changes in operating assets:		
Decrease in notes receivable	3,812	3,279
Decrease in accounts receivable	11,148	46,308
Increase in other receivable	(2,782)	(1,603)
Increase in inventories	(26,324)	(47,206)
Decrease (increase) in other current assets	8	(3,545)
Total changes in operating assets	(14,138)	(2,767)
Changes in operating liabilities:		
Decrease in contract liabilities	(1,651)	(11,576)
Increase (decrease) in notes payable	4,392	(33,904)
Increase in accounts payable	15,269	41,667
Decrease in other payables	(9,660)	(12,465)
Increase in other current liabilities	479	171
Decrease in net defined benefit liability	(49)	(51)
Total changes in operating liabilities	8,780	(16,158)
Total changes in operating assets and liabilities	(5,358)	(18,925)
Cash generated from operations	34,699	70,067
Interest received	237	899
Interest paid	(2,900)	(3,014)
Income taxes paid	(21)	(87)
Net cash flows from operating activities	32,015	67,865
Cash flows from (used in) investing activities:		
Decrease acquisition of financial assets at amortized cost	-	60,633
Acquisition of property, plant and equipment	(11,896)	(4,127)
Acquisition of intangible assets	-	(101)
Increase in prepayments for business facilities	(19,418)	(2,580)
Net cash flows from (used in) investing activities	(31,314)	53,825
Cash flows used in financing activities:		
Repayments of long-term borrowings	(14,970)	(17,404)
Payment of lease liabilities	(238)	(121)
Net cash flows used in financing activities	(15,208)	(17,525)
Net increase in cash and cash equivalents	(4,507)	104,165
Cash and cash equivalents at beginning of period	679,163	545,980
Cash and cash equivalents at end of period	\$ 664,656	650,145

See accompanying notes to financial statements.

(English Translation of Financial Statements Originally Issued in Chinese)

KENTURN NANO. TEC. CO., LTD.

Notes to the Financial Statements

March 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(1) Company history

KENTURN NANO. TEC. CO., LTD. (the “Company”) was established upon the approval of the Ministry of Economic Affairs on December 14, 1983, whose registered address is at No. 16, Zhangbin E. 7th Rd., Xianxi Township, Changhua County 507, Taiwan. The Company mainly engages in mechanical equipment and other machinery manufacturing, as well as international trade and related services.

The Company’s shares were listed on Taipei Exchange in the TPEx since June 11, 2018.

(2) Approval date and procedures of the financial statements

The financial statements were authorized for issuance by the board of directors on May 6, 2025.

(3) New standards, amendments and interpretations adopted

- (a) The impact of the IFRS Accounting Standards endorsed by the Financial Supervisory Commission, R.O.C. which have already been adopted.

The Company has initially adopted the following new amendments, which do not have a significant impact on its financial statements, from January 1, 2025:

- Amendments to IAS21 “Lack of Exchangeability”

- (b) The impact of IFRS Accounting Standards endorsed by the FSC but not yet effective

The Company’s anticipated adoption of the new amendments beginning on January 1, 2026, are expected to have the following impacts:

- (i) Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments” regarding the application guidance requirements for Section 4.1 of IFRS 9 and the related disclosure requirements of IFRS 7

For financial assets with contingent features that are not related directly to a change in basic lending risks or costs (e.g. where the cash flows change depending on whether the borrower meets an ESG target specified in the loan contract), the amendments introduce an additional test to assess the “solely payments of principal and interest on the principal amount outstanding” criterion. In accordance with the Q&A published by the FSC on February 26, 2025, the Company did not elect to early adopt the application guidance in Section 4.1 of the amendments on January 1, 2025.

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

- (c) The impact of IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

The following new and amended standards, which may be relevant to the Company, have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

Standards or Interpretations	Content of amendment	Effective date per IASB
IFRS 18 “Presentation and Disclosure in Financial Statements”	<p>The new standard introduces three categories of income and expenses, two income statement subtotals and one single note on management performance measures. The three amendments, combined with enhanced guidance on how to disaggregate information, set the stage for better and more consistent information for users, and will affect all the entities.</p> <ul style="list-style-type: none"> • A more structured income statement: under current standards, companies use different formats to present their results, making it difficult for investors to compare financial performance across companies. The new standard promotes a more structured income statement, introducing a newly defined ‘operating profit’ subtotal and a requirement for all income and expenses to be allocated between three new distinct categories based on a company’s main business activities. • Management performance measures (MPMs): the new standard introduces a definition for management performance measures, and requires companies to explain in a single note to the financial statements why the measure provides useful information, how it is calculated and reconcile it to an amount determined under IFRS Accounting Standards. • Greater disaggregation of information: the new standard includes enhanced guidance on how companies group information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes. 	January 1, 2027

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

The Company is evaluating the impact on its financial position and financial performance upon the initial adoption of the abovementioned standards or interpretations. The results thereof will be disclosed when the Company completes its evaluation.

The Company does not expect the following other new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its financial statements:

- Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”
- IFRS 17 “Insurance Contracts” and amendments to IFRS 17 “Insurance Contracts”
- IFRS 19 “Subsidiaries without Public Accountability: Disclosures”
- Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments” regarding the application guidance requirements for Sections 3.1 and 3.3 of IFRS 9 and the related disclosure requirements of IFRS 7
- Annual Improvements to IFRS Accounting Standards—Volume 11
- Amendments to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”

(4) Summary of material accounting policies

(a) Statement of compliance

These financial statements have been prepared in accordance with the preparation and guidelines of IAS 34 “Interim Financial Reporting” which are endorsed and issued into effect by FSC, and do not include all of the information required by the Regulations and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed and issued into effect by the FSC (hereinafter referred to IFRS Accounting Standards endorsed by the FSC) for a complete set of the annual financial statements.

Except the following accounting policies mentioned below, the material accounting policies adopted in the financial statements are the same as those in the financial statement for the year ended December 31, 2024. For the related information, please refer to note 4 of the financial statements for the year ended December 31, 2024.

(b) Income taxes

The income tax expenses have been prepared and disclosed in accordance with paragraph B12 of International Financial Reporting Standards 34, Interim Reporting.

Income tax expenses for the period are measured by multiplying together the pre-tax income for the interim reporting period and the management’s best estimate of effective annual tax rate. This should be recognized fully as tax expense for the current period.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

(c) Employee benefits

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year adjusted for significant.

(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty

The preparation of the financial statements in conformity with the Regulations and IAS 34 “Interim Financial Reporting” endorsed by the FSC requires management to make judgments, and estimates about the future, including climate-related risks and opportunities, that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

The preparation of the interim financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the financial statements for the year ended December 31, 2024. For related information, please refer to note 5 of the financial statements for the year ended December 31, 2024.

(6) Explanation of significant accounts

Except for the following disclosures, there were no material differences in the disclosures of significant accounts between the interim financial statements for the current period and the 2024 financial statements. Please refer to note 6 to the 2024 annual financial statements.

(a) Cash and cash equivalents

	March 31, 2025	December 31, 2024	March 31, 2024
Pretty cash and cash on hand	\$ 43	57	26
Check deposits	2,798	2,804	2,435
Time deposits	27,117	59,284	70,892
Demand deposits	<u>634,698</u>	<u>617,018</u>	<u>576,792</u>
Cash and cash equivalents in the statement of cash flows	<u><u>\$ 664,656</u></u>	<u><u>679,163</u></u>	<u><u>650,145</u></u>

(b) Financial assets measured at amortized cost

	March 31, 2025	December 31, 2024	March 31, 2024
Time deposits	<u><u>\$ -</u></u>	<u><u>-</u></u>	<u><u>19,200</u></u>

The Company has assessed that these financial assets are held-to-maturity to collect contractual cash flows, which consist solely of payments of principal and interest on principal amount outstanding. Therefore, these investments were classified as financial assets measured at amortized cost.

For credit risk information, please refer to note 6 (u).

The financial assets at amortized cost had not been pledged as collateral.

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

(c) **Notes and accounts receivable**

	March 31, 2025	December 31, 2024	March 31, 2024
Notes receivable from operating activities	\$ 3,537	7,349	3,195
Account receivable—measured as amortized cost	62,888	74,036	162,845
Less: Loss allowance	(998)	(1,594)	(3,884)
	<u><u>\$ 65,427</u></u>	<u><u>79,791</u></u>	<u><u>162,156</u></u>

The Company applies the simplified approach to provide for its expected credit losses, i.e. the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, accounts receivables have been grouped based on shared credit risk characteristics and the days past due, as well as incorporated forward looking information, the loss allowance provisions were determined as follows:

	March 31, 2025		
	Gross carrying amount	Weighted- average loss rate	Loss allowance provision
Current	\$ 65,265	-%	-
Past due less than 120 days	175	7.43%	13
121 to 240 days past due	-	-%	-
241 to 365 days past due	-	-%	-
More than 1 year past due	985	100%	985
	<u><u>\$ 66,425</u></u>		<u><u>998</u></u>

	December 31, 2024		
	Gross carrying amount	Weighted- average loss rate	Loss allowance provision
Current	\$ 79,791	-%	-
Past due less than 120 days	-	-%	-
121 to 240 days past due	-	-%	-
241 to 365 days past due	-	-%	-
More than 1 year past due	1,594	100%	1,594
	<u><u>\$ 81,385</u></u>		<u><u>1,594</u></u>

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

	March 31, 2024		
	Gross carrying amount	Weighted- average loss rate	Loss allowance provision
Current	\$ 162,156	-%	-
Past due less than 120 days	-	-%	-
121 to 240 days past due	-	-%	-
241 to 365 days past due	-	-%	-
More than 1 year past due	3,884	100%	3,884
	<u>\$ 166,040</u>		<u>3,884</u>

The movements in the allowance for notes and accounts receivables were as follows:

	For the three months ended March 31	
	2025	2024
Balance at January 1	\$ 1,594	5,203
Impairment losses reversed	(596)	(1,131)
Amounts written off	-	(188)
Balance at March 31	<u>\$ 998</u>	<u>3,884</u>

The notes and accounts receivables of the Company had not been pledged as collateral.

(d) **Inventories**

	March 31, 2025	December 31, 2024	March 31, 2024
Raw materials	\$ 38,765	21,408	41,331
Work in progress	107,807	104,871	117,701
Semi-finished goods	55,014	63,326	52,290
Finished goods	93,313	77,573	87,238
	<u>\$ 294,899</u>	<u>267,178</u>	<u>298,560</u>

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

Inventory related losses and profits were as follows:

	For the three months ended March 31	
	2025	2024
(Gains) losses on valuation of inventories	\$ (1,397)	723
Unallocated fixed manufacturing expenses	2,313	-
Revenue from sale of scraps	(182)	(520)
Operating costs	<u><u>\$ 734</u></u>	<u><u>203</u></u>

The inventories of the Company had not been pledged as collateral.

(e) Property, plant and equipment

The cost and depreciation of the property, plant and equipment of the Company were as follows:

	Land	Buildings and structures	Machinery and equipment	Transportation equipment	Other equipment	Total
Cost or deemed cost:						
Balance at January 1, 2025	\$ 458,387	727,725	627,947	19,594	19,433	1,853,086
Additions	-	4,149	17,813	-	305	22,267
Reclassification	-	-	1,197	-	-	1,197
Balance at March 31, 2025	<u><u>\$ 458,387</u></u>	<u><u>731,874</u></u>	<u><u>646,957</u></u>	<u><u>19,594</u></u>	<u><u>19,738</u></u>	<u><u>1,876,550</u></u>
Balance at January 1, 2024	\$ 458,387	721,932	604,120	14,136	17,143	1,815,718
Additions	-	290	1,204	-	188	1,682
Balance at March 31, 2024	<u><u>\$ 458,387</u></u>	<u><u>722,222</u></u>	<u><u>605,324</u></u>	<u><u>14,136</u></u>	<u><u>17,331</u></u>	<u><u>1,817,400</u></u>
Depreciation :						
Balance at January 1, 2025	\$ -	196,680	384,504	7,805	11,982	600,971
Depreciation	-	6,388	10,564	837	902	18,691
Balance at March 31, 2025	<u><u>\$ -</u></u>	<u><u>203,068</u></u>	<u><u>395,068</u></u>	<u><u>8,642</u></u>	<u><u>12,884</u></u>	<u><u>619,662</u></u>
Balance at January 1, 2024	\$ -	169,463	344,973	9,634	8,784	532,854
Depreciation	-	6,651	9,806	395	745	17,597
Balance at March 31, 2024	<u><u>\$ -</u></u>	<u><u>176,114</u></u>	<u><u>354,779</u></u>	<u><u>10,029</u></u>	<u><u>9,529</u></u>	<u><u>550,451</u></u>
Carrying amounts:						
Balance at January 1, 2025	<u><u>\$ 458,387</u></u>	<u><u>531,045</u></u>	<u><u>243,443</u></u>	<u><u>11,789</u></u>	<u><u>7,451</u></u>	<u><u>1,252,115</u></u>
Balance at March 31, 2025	<u><u>\$ 458,387</u></u>	<u><u>528,806</u></u>	<u><u>251,889</u></u>	<u><u>10,952</u></u>	<u><u>6,854</u></u>	<u><u>1,256,888</u></u>
Balance at January 1, 2024	<u><u>\$ 458,387</u></u>	<u><u>552,469</u></u>	<u><u>259,147</u></u>	<u><u>4,502</u></u>	<u><u>8,359</u></u>	<u><u>1,282,864</u></u>
Balance at March 31, 2024	<u><u>\$ 458,387</u></u>	<u><u>546,108</u></u>	<u><u>250,545</u></u>	<u><u>4,107</u></u>	<u><u>7,802</u></u>	<u><u>1,266,949</u></u>

Property, plant and equipment pledged as collateral for long-term borrowings; please refer to note 8.

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

(f) **Right-of-use assets**

The Company leases other equipment classified as right-of-use assets, the cost and depreciation of right-of-use assets of the Company were as follows:

	<u>Other equipment</u>
Cost:	
Balance at January 1, 2025	
(Balance as of March 31, 2025)	\$ <u><u>2,874</u></u>
Balance at January 1, 2024	\$ 1,200
Additions	<u>1,674</u>
Balance at March 31, 2024	\$ <u><u>2,874</u></u>
Accumulated depreciation:	
Balance at January 1, 2025	\$ 674
Depreciation for the year	<u>144</u>
Balance at March 31, 2025	\$ <u><u>818</u></u>
Balance at January 1, 2024	\$ 100
Depreciation for the year	<u>143</u>
Balance at March 31, 2024	\$ <u><u>243</u></u>
Carrying amounts:	
Balance at January 1, 2025	\$ <u><u>2,200</u></u>
Balance at March 31, 2025	\$ <u><u>2,056</u></u>
Balance at January 1, 2024	\$ <u><u>1,100</u></u>
Balance at March 31, 2024	\$ <u><u>2,631</u></u>

(g) **Intangible Assets**

The costs of intangible assets and amortization of the Company were as follows:

	<u>Computer software</u>
Carrying amounts:	
Balance at January 1, 2025	\$ <u><u>11,546</u></u>
Balance at March 31, 2025	\$ <u><u>10,539</u></u>
Balance at January 1, 2024	\$ <u><u>6,076</u></u>
Balance at March 31, 2024	\$ <u><u>5,613</u></u>

There were no significant additions, disposal, or recognition and reversal of impairment losses of intangible assets for the three months ended March 31, 2025 and 2024. Information on amortization for the period is discussed in note 12(a). Please refer to note 6(g) to the 2024 annual financial statements for other related information.

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

(h) **Other current assets and other non-current assets**

The other current assets and other non-current assets of the Company were as follows:

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Other current assets:			
Other receivables	\$ 6,834	4,052	4,832
Prepaid expenses	8,961	8,989	1,071
Prepayments to suppliers	<u>20</u>	<u>-</u>	<u>4,315</u>
	<u><u>\$ 15,815</u></u>	<u><u>13,041</u></u>	<u><u>10,218</u></u>
Other non-current assets:			
Prepayments for equipment	\$ 26,194	7,973	2,580
Refundable deposits	<u>10</u>	<u>10</u>	<u>10</u>
	<u><u>\$ 26,204</u></u>	<u><u>7,983</u></u>	<u><u>2,590</u></u>

For credit risk information, please refer to note 6(u).

(i) **Short-term borrowings**

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Unsecured bank loans	<u>\$ 50,000</u>	<u>50,000</u>	<u>50,000</u>
Unused short-term credit lines	<u>\$ 100,000</u>	<u>100,000</u>	<u>100,000</u>
Range of internet rates	<u>1.725%</u>	<u>1.725%</u>	<u>1.60%</u>

There were no significant issues and repayments of short-term borrowings for the three months ended March 31, 2025 and 2024. For interest expense, please refer to note 6(t).

(j) **Other payables**

The other payables were summarized as follows:

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Payable on construction and equipment	\$ 22,381	12,010	1,658
Accrued expenses and other	<u>71,377</u>	<u>81,056</u>	<u>63,140</u>
	<u><u>\$ 93,758</u></u>	<u><u>93,066</u></u>	<u><u>64,798</u></u>

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

(k) Other current liabilities

The other current liabilities were summarized as follows:

	March 31, 2025	December 31, 2024	March 31, 2024
Deferred revenue	\$ 4,190	4,190	16,008
Receipts under custody	2,761	2,307	2,224
Temporary receipts	135	110	85
	<u>\$ 7,086</u>	<u>6,607</u>	<u>18,317</u>

(l) Long-term borrowings

The details of long-term borrowings of the Company were as follows:

	March 31, 2025	December 31, 2024	March 31, 2024
Unsecured bank loans	\$ -	-	5,000
Secured bank loans	544,075	559,045	603,813
Less: current portion	(60,108)	(60,016)	(64,829)
	<u>\$ 483,967</u>	<u>499,029</u>	<u>543,984</u>
Unused long-term credit lines	\$ -	-	-
Range of internet rates	<u>1.915%~1.95%</u>	<u>1.915%~1.95%</u>	<u>1.79%~2.1285%</u>

(i) The additional and repayments of borrowings

For the three months ended March 31, 2025 and 2024, the Company had no additional long-term borrowings; and the repayments amounted to \$14,970 thousand and \$17,404 thousand, respectively. For interest expense, please refer to note 6(t).

(ii) Collateral for long-term borrowings

For the collateral for long-term borrowings, please refer to note 8.

(m) Lease liabilities

The carrying amount of the Company's lease liabilities were as follows:

	March 31, 2025	December 31, 2024	March 31, 2024
Current	\$ 965	961	949
Non-current	<u>563</u>	<u>805</u>	<u>1,527</u>

For the maturity analysis, please refer to note 6(u).

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

The amounts recognized in profit or loss were as follows:

	For the three months ended March 31	
	2025	2024
Interest on lease liabilities	\$ <u>7</u>	<u>10</u>
Expenses relating to short-term leases	\$ <u>810</u>	<u>858</u>

The amounts recognized in the statement of cash flows by the Company were as follows:

	For the three months ended March 31	
	2025	2024
Total cash outflow for leases	\$ <u>1,055</u>	<u>989</u>

(i) Other equipment leases

The Company leases other equipment, with lease terms of three years. The Company has options to purchase the assets at the end of the contract term;

(ii) Other leases

The Company also leases other equipment with contract terms of one year. These leases are short-term and/or leases of low-value items. The Company has elected not to recognize right-of-use assets and lease liabilities for these leases.

(n) **Employee benefits**

(i) Defined benefit plans

There was no material volatility of the market, no material reimbursement and settlement or other material onetime events since prior fiscal year. As a result, the pension cost in the accompanying interim period was measured and disclosed according to the actuarial report as of December 31, 2024 and 2023.

The detail for the Company's expense were as follows:

	For the three months ended March 31	
	2025	2024
Administration expenses	\$ <u>41</u>	<u>38</u>

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

(ii) Defined contribution plans

The Company's expenses for the pension plan contributions to the Bureau of Labor Insurance were as follows:

	For the three months ended March 31	
	2025	2024
Operating cost	\$ 1,048	967
Selling expenses	106	134
Administration expenses	282	209
Research and development expenses	134	93
	<u><u>\$ 1,570</u></u>	<u><u>1,403</u></u>

(o) **Income Taxes**

The components of income tax were as follows:

	For the three months ended March 31	
	2025	2024
Current tax expense		
Current period	\$ <u><u>3,913</u></u>	<u><u>13,798</u></u>

The Company's tax returns for the years through 2023 were assessed and approved by the tax authorized.

(p) **Capital and Other Equity**

- (i) Except for the following disclosure, there was no significant change in capital and other equity for the periods from January 1 to March 31, 2025 and 2024. For the related information, please refer to note 6(p) to the financial statements for the year ended December 31, 2024.

(ii) Retained Earnings

The Company's article of incorporation stipulate that Company's net earnings should first be used to offset the prior years' deficits, if any, before paying any income taxes. Of the remaining balance, 10% is to be appropriated as legal reserve, and then any remaining profit together with any undistributed retained earnings shall be distributed according to the distribution plan proposed by the Board of Directors and submitted to the stockholders' meeting for approval.

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

The Company's dividend policy is based on the Company's sustainable operation, cost stability, safeguarding the shareholders' rights and interests, and improving the financial structure, wherein the Board of Directors formulates a surplus distribution plan according to the Company's capital needs. If the Company decided to distribute its earnings by cash, the distribution ratio shall not be less than 10% of the total dividends of the shareholders, and has to be decided during the shareholders' meeting. Any adjustment made to the above ratio according to the actual profit and capital situation of the current year shall be proposed by the board during the shareholders' meeting for approval.

1) Legal reserve

When a company incurs no loss, it may, pursuant to a resolution by a shareholders' meeting, distribute its legal reserve by issuing new shares or by distributing cash, and only the portion of legal reserve which exceeds 25% of capital may be distributed.

2) Earnings distribution

The amount of cash dividends for 2024 earnings distribution had been proposed during the Board of Directors held on March 6, 2025; while the earnings distribution for 2023 were decided via the general meeting of the shareholders held on June 25, 2024, respectively. The relevant dividend distributions to shareholders were as follows:

	2024		2023	
	Amount per share	Total amount	Amount per share	Total amount
Dividends distributed to ordinary shareholders				
Cash	\$ <u>1.20</u>	<u>70,226</u>	<u>1.00</u>	<u>58,522</u>

(q) **Earnings per Share**

The calculation of basic earnings per share and diluted earnings per share were as follows:

	For the three months ended March 31	
	2025	2024
Basic earnings per share		
Profit attributable to ordinary shareholders of the Company	\$ <u>15,651</u>	<u>55,193</u>
Weighted average number of outstanding ordinary shares (in thousands)	<u>58,522</u>	<u>58,522</u>
	\$ <u>0.27</u>	<u>0.94</u>

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

	<u>2025</u>	<u>2024</u>
Diluted earnings per share		
Profit attributable to ordinary shareholders of the Company	\$ <u><u>15,651</u></u>	<u><u>55,193</u></u>
Weighted average number of ordinary shares (in thousands)	58,522	58,522
Effect of dilutive potential ordinary shares		
Effect of employee shares bonus	<u>270</u>	<u>493</u>
Weightier-average number of ordinary shares (in thousands) (diluted)	<u><u>58,792</u></u>	<u><u>59,015</u></u>
	\$ <u><u>0.27</u></u>	<u><u>0.94</u></u>
(r) Revenue from contracts with customers		

(i) Details of revenue

	For the three months ended March 31	
	<u>2025</u>	<u>2024</u>
<u>Primary geographical markets</u>		
China	\$ 156,671	168,560
Taiwan	40,651	89,903
India	15,905	16,620
Other	<u>1,564</u>	<u>1,517</u>
	\$ <u><u>214,791</u></u>	<u><u>276,600</u></u>
<u>Major products/services lines</u>		
Precision spindles and consumables	\$ <u><u>214,791</u></u>	<u><u>276,600</u></u>

(ii) Contract balances

	<u>March 31, 2025</u>	<u>December 31, 2024</u>	<u>March 31, 2024</u>
Contract liabilities	\$ <u><u>7,565</u></u>	<u><u>9,216</u></u>	<u><u>25,043</u></u>

- 1) Contract liabilities are mainly pre-receipts.
- 2) For details on accounts receivable , notes receivable and allowance for impairment, please refer to note 6 (c).

The amount of revenue recognized for the three months ended March 31, 2025 and 2024 , that was included in the contract liability balance at the beginning of the period were \$3,899 thousand and \$12,865 thousand.

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

(s) Employee compensation and directors' remuneration

In accordance with the articles of incorporation, the Company should contribute not less than 1% and not more than 15% of the profit as employee remuneration. The recipients of shares and cash may include the employees of the Company's subsidiaries who meet certain conditions. The directors shall be entitled to a maximum of 5% of the above amount of profits as their remuneration, with the approval of the board. Both remuneration to employees and directors should be reported during the shareholders' meeting. However, if the Company has accumulated deficits, the profit should be reserved to offset the deficit. In addition, the remuneration of employees and directors shall be allocated in accordance with the proportion set forth in the preceding paragraph.

For the three months ended March 31, 2025 and 2024, the Company estimated its employee remuneration amounting to \$3,650 thousand and \$4,025 thousand, respectively, and directors' remuneration amounting to \$550 thousand and \$675 thousand, respectively. These amounts were calculated using the Company's pre-tax income for each period before deducting the remunerations of employees and directors, multiplied by the proposed percentages of remunerations of employees and directors, as stated in the Company's Articles of Incorporation. These remunerations were expensed under operating costs or expenses for each period. If there are any subsequent adjustments to the actual remuneration amounts after the annual shareholders' meeting, the adjustments will be regarded as changes in accounting estimates and will be reflected in profit or loss in the following year. Shares distributed to employees as remuneration were calculated based on the closing price of the Company's shares on the day before the approval by the Board of Directors.

For the years ended December 31, 2024 and 2023, the Company estimated its employee remuneration amounting to \$19,500 thousand and \$16,100 thousand, respectively, and directors' remuneration amounting to \$3,200 thousand and \$2,700 thousand, respectively. There were no differences to the actual remuneration paid. Related information would be available at the Market Observation Post System website.

(t) Non-operating Income and Expenses

(i) Interest income

The details of the interest income were as follows:

	For the three months ended	
	March 31	
	2025	2024
Interest income from bank deposits	\$ <u><u>237</u></u>	<u><u>899</u></u>

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

(ii) Other income

The details of other income were as follows:

		For the three months ended March 31	
		2025	2024
Government subsidy	\$	42	126
Others		12	11
	\$	<u>54</u>	<u>137</u>

(iii) Other gains and losses

The details of other gains and losses were as follows:

		For the three months ended March 31	
		2025	2024
Foreign exchange gains	\$	<u>9,798</u>	<u>12,958</u>

(iv) Finance costs

The details of finance costs were as follows:

		For the three months ended March 31	
		2025	2024
Interest expense - bank loans	\$	2,874	2,994
Interest expense - lease liabilities		7	10
	\$	<u>2,881</u>	<u>3,004</u>

(u) **Financial Instruments**

Except for the contention mentioned below, there was no significant change in the fair value of the Company's financial instruments and degree of exposure to credit risk, liquidity risk and market risk arising from financial instruments. For related information, please refer to note 6(u) to the financial statements for the year ended December 31, 2024.

(i) Credit risk

1) Credit risk exposure

The carrying amount of financial assets represents the maximum amount exposed to credit risk.

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

2) Concentration of credit risk

As of March 31, 2025, December 31 and March 31, 2024, 70%, 74% and 80%, respectively, of trade receivables were five major customers. Thus, credit risk is significantly centralized.

3) Receivables of credit risk

For credit risk exposure of note and trade receivables, please refer to note 6(c).

Other financial assets at amortized cost includes other receivables and time deposits . All of these financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited to 12 months expected losses. The Company has no loss allowance provision for the three months ended March 31, 2025 and 2024.

(ii) Liquidity risk

The following table shows the contractual maturities of financial liabilities, including estimated interest payments and excluding the impact of netting agreements.

	<u>Carrying amount</u>	<u>Contractual cash flows</u>	<u>With 1 year</u>	<u>1-2 years</u>	<u>2-5 years</u>	<u>Over 5 years</u>
March 31, 2025						
Non-derivative financial liabilities						
Short-term borrowings	\$ 50,000	50,362	50,362	-	-	-
Notes and accounts payable and other payables	290,760	290,760	290,760	-	-	-
Long-term borrowings (Including due within one year)	544,075	604,318	70,124	69,334	186,188	278,672
Lease liabilities	1,528	1,546	981	565	-	-
	<u>\$ 886,363</u>	<u>946,986</u>	<u>412,227</u>	<u>69,899</u>	<u>186,188</u>	<u>278,672</u>
December 31, 2024						
Non-derivative financial liabilities						
Short-term borrowings	\$ 50,000	50,147	50,147	-	-	-
Notes and accounts payable and other payables	270,407	270,407	270,407	-	-	-
Long-term borrowings (Including due within one year)	559,045	621,973	70,322	69,532	189,591	292,528
Lease liabilities	1,766	1,791	981	810	-	-
	<u>\$ 881,218</u>	<u>944,318</u>	<u>391,857</u>	<u>70,342</u>	<u>189,591</u>	<u>292,528</u>
March 31, 2024						
Non-derivative financial liabilities						
Short-term borrowings	\$ 50,000	50,329	50,329	-	-	-
Notes and accounts payable and other payables	340,739	340,739	340,739	-	-	-
Long-term borrowings (Including due within one year)	608,813	675,464	75,298	69,521	198,387	332,258
Lease liabilities	2,476	2,527	981	981	565	-
	<u>\$ 1,002,028</u>	<u>1,069,059</u>	<u>467,347</u>	<u>70,502</u>	<u>198,952</u>	<u>332,258</u>

The Company does not expect the cash flows included in the maturity analysis to occur significantly earlier or at significantly different amounts.

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

(iii) Market risk

1) Currency risk

The Company's significant exposure to foreign currency risk was as follows:

	March 31, 2025				December 31, 2024			March 31, 2024		
	Foreign currency	Exchange rate		TWD	Foreign currency	Exchange rate	TWD	Foreign currency	Exchange rate	TWD
<u>Financial assets</u>										
<u>Monetary items</u>										
USD	USD	1,914	33.205	63,554	4,110	32.785	134,746	3,776	32.000	120,832
RMB	RMB	22,344	4.573	102,179	62,137	4.478	278,249	78,018	4.408	343,903

The Company's exposure to foreign currency risk arises from the translation of the foreign currency exchange gains and losses on cash and cash equivalents, trade receivables that are denominated in foreign currency. A strengthening (weakening) of 1% of the TWD against the foreign currency as of March 31, 2025 and 2024 would have increased (decreased) the net profit after tax by \$1,326 thousand and \$3,718 thousand, respectively. The analysis assumes that all other variables remain constant and ignores any impact of forecasted sales and purchases. The analysis is performed on the same basis for prior year.

Since the Company's functional currency is NTD, the exchange gains and losses of its monetary items are accounted for as exchange in profit or loss (including realized and unrealized), and refer to note 6(t).

2) Interest rate risk

Please refer to the notes on liquidity risk management and interest rate exposure of the Company's financial liabilities.

The following sensitivity analysis is based on the exposure to the interest rate risk of derivative and non-derivative financial instruments on the reporting date. Regarding assets with variable interest rates, the analysis is based on the assumption that the amount of assets outstanding at the reporting date was outstanding throughout the year. The rate of change is expressed as the interest rate increases or decreases by 1% when reporting to management internally, which also represents the Company management's assessment of the reasonably possible interest rate change.

If the interest rate had increased / decreased by 1 basis points, the Company's net income would have increased / decreased by \$1,188 thousand and \$1,318 thousand for the three months ended March 31, 2025 and 2024, respectively. This is mainly due to the Company's borrowing in variable rates.

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

(iv) Fair value of financial instruments

1) Categories and fair value of financial instruments

The carrying amount and fair value of the Company's financial assets and liabilities, including the information on fair value hierarchy were as follows; however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and for equity investments that has no quoted prices in the active markets and whose fair value cannot be reliably measured, disclosure of fair value information is not required:

March 31, 2025					
	<u>Book value</u>	<u>Fair Value</u>			<u>Total</u>
		<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	
Financial assets measured at amortized cost					
Cash and cash equivalents	\$ 664,656	-	-	-	-
Notes receivable, accounts receivable and other receivables	72,261	-	-	-	-
Guarantee deposits	10	-	-	-	-
	<u>\$ 736,927</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Financial liabilities at amortized cost					
Short-term borrowings	\$ 50,000	-	-	-	-
Notes payable, accounts payable and other payables	290,760	-	-	-	-
Long-term borrowings (Including due within one year)	544,075	-	-	-	-
Lease liabilities	1,528	-	-	-	-
	<u>\$ 886,363</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
December 31, 2024					
	<u>Book value</u>	<u>Fair Value</u>			<u>Total</u>
		<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	
Financial assets measured at amortized cost					
Cash and cash equivalents	\$ 679,163	-	-	-	-
Notes receivable, accounts receivable and other receivables	83,843	-	-	-	-
Guarantee deposits	10	-	-	-	-
	<u>\$ 763,016</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

		December 31, 2024			
		Fair Value			
	Book value	Level 1	Level 2	Level 3	Total
Financial liabilities at amortized cost					
Short-term borrowings	\$ 50,000	-	-	-	-
Notes payable, accounts payable and other payables	270,407	-	-	-	-
Long-term borrowings (Including due within one year)	559,045	-	-	-	-
Lease liabilities	1,766	-	-	-	-
	<u>\$ 881,218</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
		March 31, 2024			
		Fair Value			
	Book value	Level 1	Level 2	Level 3	Total
Financial assets measured at amortized cost					
Cash and cash equivalents	\$ 650,145	-	-	-	-
Financial assets measured at amortized cost	19,200	-	-	-	-
Notes receivable, accounts receivable and other receivables	166,988	-	-	-	-
Guarantee deposit	10	-	-	-	-
	<u>\$ 836,343</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Financial liabilities at amortized cost					
Short-term borrowings	\$ 50,000	-	-	-	-
Notes payable, accounts payable and other payables	340,739	-	-	-	-
Long-term borrowings (Including due within one year)	608,813	-	-	-	-
Lease liabilities	2,476	-	-	-	-
	<u>\$ 1,002,028</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

2) Valuation techniques for financial instruments not measured at fair value

The Company's valuation techniques and assumptions used for financial instruments not measured at fair value are as follows:

For financial liabilities measured at amortized cost, if there is quoted price generated by transactions, the recent transaction price and quoted price data is used as the basis for fair value measurement. However, if no quoted prices are available, the discounted cash flows are used to estimate fair values.

3) Valuation techniques for financial instruments measured at fair value

A financial instrument is regarded as being quoted in an active market if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency and those prices represent actual and regularly occurring market transactions on an arm's-length basis. Whether transactions are taking place 'regularly' is a matter of judgment and depends on the facts and circumstances of the market for the instrument.

Quoted market prices may not be indicative of the fair value of an instrument if the activity in the market is infrequent, the market is not well-established, only small volumes are traded, or bid-ask spreads are very wide. Determining whether a market is active involves judgment.

4) Transfers between Level 1 and Level 2

There were no transfers from Level 1 to another in 2025 and 2024 .

(v) Financial risk management

There were no significant changes in the Company's financial risk management and policies as disclosed in note 6(v) to the financial statements for the year ended December 31, 2024.

(w) Capital management

Management believes that the objectives, policies and processes of capital management of the Company has been applied consistently with those described in the financial statements for the year ended December 31, 2024. Also, management believes that there were no significant changes in the Company's capital management information as disclosed for the year ended December 31, 2024. Please refer to note 6(w) to the financial statements for the year ended December 31, 2024 for further details.

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

(x) Investing and financing activities not affecting current cash flow

For the Company's investing and financing activities, which did not affect the current cash flow in the three months ended March 31, 2025 and 2024 on its right-of-use assets through lease, please refer to note 6(f).

Reconciliation of liabilities arising from financing activities were as follows:

	January 1, 2025	Cash flows	Non-cash changes		March 31, 2025
			Additions/ Reclassification	Fair value movement	
Short-term borrowings	\$ 50,000	-	-	-	50,000
Long-term borrowings (including due within one year)	559,045	(14,970)	-	-	544,075
Lease liabilities	1,766	(238)	-	-	1,528
Total liabilities from financing activities	<u>\$ 610,811</u>	<u>(15,208)</u>	<u>-</u>	<u>-</u>	<u>595,603</u>

	January 1, 2024	Cash flows	Non-cash changes		March 31, 2024
			Additions/ Reclassification	Fair value movement	
Short-term borrowings	\$ 50,000	-	-	-	50,000
Long-term borrowings (including due within one year)	626,217	(17,404)	-	-	608,813
Lease liabilities	1,037	(121)	1,560	-	2,476
Total liabilities from financing activities	<u>\$ 677,254</u>	<u>(17,525)</u>	<u>1,560</u>	<u>-</u>	<u>661,289</u>

(7) Related-party transactions

Key management personnel compensation:

	For the three months ended March 31	
	2025	2024
Short-term employee benefits	\$ 2,439	2,292
Post-employment benefits	-	-
Other long-term benefits	-	-
Termination benefits	-	-
Share-based payments	-	-
	<u>\$ 2,439</u>	<u>2,292</u>

(8) Pledged assets

The carrying values of pledged assets were as follows:

Pledged assets	Object	March 31, 2025	December 31, 2024	March 31, 2024
Land	Guarantee for bank loans	\$ 458,387	458,387	458,387
Buildings and structures	Guarantee for bank loans	528,806	531,045	546,108
Machinery and equipment	Guarantee for bank loans	158,723	165,257	183,691
		<u>\$ 1,145,916</u>	<u>1,154,689</u>	<u>1,188,186</u>

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

(9) Commitments and contingencies

Unrecognized contractual commitments

	March 31, 2025	December 31, 2024	March 31, 2024
Acquisition of property, plant and equipment	\$ <u>32,704</u>	<u>66,992</u>	<u>33,039</u>

(10) Losses due to major disasters:None

(11) Subsequent Events:None

(12) Other

- (a) A summary of current-period employee benefits, depreciation, and amortization, by function, is as follows:

	For the three months ended March 31					
	2025			2024		
	Cost of Sale	Operating Expense	Total	Cost of Sale	Operating Expense	Total
By item						
Employee benefits						
Salary	24,908	21,291	46,199	25,438	17,544	42,982
Labor and health insurance	2,773	2,032	4,805	2,484	1,174	3,658
Pension	1,048	563	1,611	967	474	1,441
Others	804	754	1,558	838	920	1,758
Depreciation	15,562	3,273	18,835	14,736	3,004	17,740
Amortization	153	854	1,007	8	556	564

- (b) Seasonality of operationsn

The Company's operations were not affected by seasonality or cyclicity factors.

(Continued)

KENTURN NANO. TEC. CO., LTD.
Notes to the Financial Statements

(13) Other disclosures

(a) Information on significant transactions:None

The following is the information on significant transactions required by the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” for the Company for the three months ended March 31, 2025:

(i) Loans to other parties:None

(ii) Guarantees and endorsements for other parties:None

(iii) Securities held as of March 31, 2025 (excluding investment in subsidiaries, associates and joint ventures):None

(iv) Related-party transactions for purchases and sales with amounts exceeding the lower of NT\$100 million or 20% of the capital stock:None

(v) Receivables from related parties with amounts exceeding the lower of NT\$100 million or 20% of the capital stock:None

(b) Information on investees:None

(c) Information on investment in Mainland China:None

(14) Segment information

The reportable information of segment's profit and assets is in accordance with the financial statements. Please refer to Statements of Financial Position and Statements of Comprehensive Income.